Abstracts tagged "lung and myositis"

Abstract Number: 283 • 2016 ACR/ARHP Annual Meeting
Extracellular Histidyl-tRNA Synthetase in Myositis
Catia Fernandes-Cerqueira¹, Azita Sohrabian², Inka Albrecht¹, Antonella Notarnicola¹, Elena Ossipova¹, Johan Lengqvist¹, Kim Kultima³, Maryam Fathi⁴, Ger JM Pruijn⁵, Johan Grunewald⁴, Johan Rönnelid², Ingrid E. Lundberg¹ and Per-Johan Jakobsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Immunology Genetics and Pathology,Uppsala University, Uppsala, Sweden, ³Department of Medical Sciences, Cancer Pharmacology and Computational Medicine, Uppsala University, Uppsala, Sweden, ⁴Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands
Background/Purpose: Histidyl-transfer RNA synthetase (HisRS, Jo-1) is a major autoantigen in myositis with lung involvement1-4. Simultaneous presence of anti-Jo-1 and anti-Ro52 antibodies has been demonstrated…
Abstract Number: 219 • 2012 ACR/ARHP Annual Meeting
Significant Functional Improvement Using Aggressive Immunomodulatory Therapy in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Ramona Mihu¹, Roger D. Rossen², Jovan Popovich³ and Sandra L. Sessoms¹, ¹Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, ³Medicine/Rheumatology, The Methodist Hospital, Houston, TX
Background/Purpose: Pulmonary disease in patients with idiopathic inflammatory myopathies, polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM) is a major cause of morbidity. Approximately…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].